Kit Rapid Test BD Veritor™ System Antigen Detection SARS-CoV-2 / Influenza A + B Direct Anterior Nasal Swab Sample 30 Tests by BD ID 256088

188-1-6088
      
Stock Est. Shipping Date: 25th April 2025

Kit Rapid Test BD Veritor™ System Antigen Detection SARS-CoV-2 / Influenza A + B Direct Anterior Nasal Swab Sample 30 Tests
Sold by: KT OF 30

 Reviews
Better together

  • Total: $0.00

Rally #188-1-6088
BD #256088
BD Veritor™ Plus System SARS-CoV-2 & Flu A+B Kit (30 Test/KT)

Respiratory Test Kit, SARS-COV-2/FLU A+B, Rapid Chromatographic Digital Immunoassay, Anterior Nasal Swab, Rx Only

BD Veritor™ Mix & Match Promotional Offerings

Save On BD Veritor™ Rapid Antigen Tests!

Buy 4 BD Kits Of Any Combination, Get 1 at No Additional Cost
(1 Kit = 30 Tests)

Offer Valid Through March 31, 2025


See Details Below
Features
  • May help reduce manual test processing errors with its easy operation and single-button functionality
  • Displays easy-to-read digital results for COVID-19 and Flu A+B in 15 minutes
  • Provides clear, objective results by correcting for nonspecific binding and detecting positives not recognized by the unaided eye
  • Adapts easily to your workflow by offering 2 operational modes: Walk Away and Analyze Now
  • Captures or downloads the lot number, patient/specimen ID, operator ID, and test records using the BD Veritor™ InfoWiFi module
The BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B is a rapid chromatographic digital immunoassay intended for the in vitro, simultaneous qualitative detection and differentiation of SARS-CoV-2 nucleocapsid antigen and/or influenza A and B nucleoprotein antigens directly from anterior nasal swab samples taken from individuals who are suspected of a viral respiratory infection consistent with COVID-19 by a healthcare provider, within the first six days of symptom onset.

This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

This test is not intended to detect influenza C antigens. Results are for the simultaneous identification of SARS-CoV-2 nucleocapsid protein and Influenza A and B viral nucleoproteins.

Negative results should be treated as presumptive, do not rule out either Influenza or SARS-CoV-2, and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions.

Important Note:
  • Product is non-returnable; please make sure it is the right product before ordering.
  • If put into refrigeration, do not freeze.
  • For in vitro diagnostic use.
  • The test kit is intended for use with the analyzer.
  • For use under an Emergency Use Authorization (EUA) only.
  • For more information on this product's EUA, please go to the EUA section below.
For the State of California:
Warning: This product can expose you to chemicals known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.

×
Rally #188-1-6088
Manufacturer #256088
GTIN00382902560883
BrandBD Veritor™ System
ManufacturerBD
Country of OriginUnknown
ApplicationRespiratory Test Kit
For Use WithFor use with the BD Veritor™ Plus Analyzer running Firmware version 5.50 or later
Number of Tests30 Tests
Reading TypeMachine Read
Sample TypeNasal Swab Sample
SpecialtyImmunoassay
Test FormatTest Device Format
Test Kit TypeRapid
Test MethodChromatographic Digital Immunoassay
Test NameSARS-CoV-2 / Influenza A + B
Test TypeAntigen Detection
Time to Results15 Minute Results
UNSPSC Code41116020
Storage Temperature2-30 °C (Do not Freeze)
Shelf Life (Days)485

Type PPA NPA Results In
SARS-CoV-2 86.7%
(95% CI, 75.8%-93.1%)
99.5%
(95% CI, 97.4%-99.9%)
15 minutes
Influenza A 82.7%
(95% CI, 74.9%-88.5%)
97.5%
(95% CI, 95.7%-98.5%)
15 minutes
Influenza B 80.7%
(95% CI, 70.3%-88.1%)
98.2%
(95% CI, 95.7%-99.3%)
15 minutes

PPA = positive percent agreement
NPA = negative percent agreement



×
Configurations
Product ID Description Unit of Measure
256066 BD Veritor™ Plus Analyzer 1/EA
256088 Veritor SARS-COV-2 & FLU A+B Test Kit 30 Tests/Kit
256087 Veritor SARS-COV-2 Control Swab Set 10 paired controls / EA
256095 Combo Veritor Plus SARS-COV-2 FLU A+B (2 Kits of 256088 + 1 of 256066 Analyzer) 1 Kit
×
BD Veritor™ Plus System SARS-CoV-2 & Flu A+B Kit - 256088 Contents:
Kit Component Quantity Description
BD Veritor™ System Test Devices 30 single use test devices Foil pouched test device containing one reactive strip containing:

  • Murine anti-SARS coronavirus monoclonal antibodies
  • Murine anti-flu A monoclonal antibodies
  • Murine anti-flu B monoclonal antibodies
  • Biotin coupled to bovine protein
  • Murine and Leporine anti-SARS coronavirus, murine anti-flu A, anti-flu B and anti-biotin monoclonal antibodies conjugated to detector reagents are bound in the sample delivery area
Extraction Reagent 30 single use reaction tubes, each with 400 µL extraction reagent and having an integral dispensing tip Detergent solution with less than 0.1% sodium azide (preservative)
Specimen Sampling Swabs 30 sterile, single use specimen sampling swabs For sample collection and transfer
SARS-CoV-2 (+) Control Swab 1 each – individually wrapped for single use SARS-CoV-2 antigen (inactive recombinant nucleocapsid protein) with less than 0.1% sodium azide
Flu A (+) Control Swab 1 each – individually wrapped for single use Influenza A antigen (inactive recombinant nucleoprotein) with less than 0.1% sodium azide
Flu B (+) Control Swab 1 each – individually wrapped for single use Influenza B antigen (inactive recombinant nucleoprotein) with less than 0.1% sodium azide
Paperboard Tube Stands 3 each Each stand has capacity for 10 extraction reagent tubes
Assay Documentation 1 each – Instructions for use
1 each – Quick reference instruction card
1 each – Nasal sampling instructions

×

BD Veritor™ Mix & Match Promotional Offer

Save on BD Veritor™ rapid antigen tests!

Buy 4 kits, get 1 at no additional cost.
(1 Kit = 30 Tests)

Mix & Match: Promotional offerings available in any combination (below).

Offer valid through March 31, 2025 Only.

Promotional Items
BD Item NumberDescription
256088 BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 & Influenza A+B
256082 BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2
256045 BD Veritor™ Plus System for Rapid Detection of Influenza A+B CLIA-Waived
256041 BD Veritor™ Plus System for Rapid Detection of Influenza A+B (moderate complexity)
256038 BD Veritor™ Plus System for Rapid Detection of Respiratory Syncytial Virus (RSV) CLIA-Waived

Note: Offer excludes Group A Strep kits and RSV Moderate Complexity kits.

To receive your promotional item(s), customers will need to complete a form provided by BD, and upload the proof of purchase.

The customer will receive a Proof of Purchase from Rally Inc. after purchasing the product. However, the promotional offer is handled solely between you, the customer, and the manufacturer, BD (Becton, Dickinson and Company). Rally Inc. does not oversee these offers. To check eligibility for the promotion and receive your promotional item, please follow the manufacturer's online instructions.

Note: Some items are under Emergency Use Authorization, please check their EUA before purchasing.

You can find more informations on this product's promotion and the required form here.



×

- Reimbursements Information -

This product maybe reimbursable, depending on various factors including current law and policies. Rally Inc. does not handle these reimbursements; instead, each reimbursement is handled solely between you, the customer, and the manufacturer, BD. Rally Inc. does not oversee these reimbursements. To check eligibility and get your reimbursements, please follow the manufacturer's reimbursements instructions.

You can find more informations on reimbursement details here.

×

EUA - Emergency Use Authorization

In the USA, this product has not been FDA cleared or approved; but has been authorized by FDA under an Emergency Use Authorization. This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, in the USA, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 under Section 564(b)(1) of Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or the authorization is revoked sooner.


No recommended products at the moment.